Current Drug Discovery for Anti-hepatitis C Virus Targeting NS4B

Area of Science:

• Virology
• Medicinal Chemistry
• Drug Discovery

Background:

• Hepatitis C virus (HCV) poses a significant global health challenge, infecting over 170 million people worldwide.
• Current treatments focus on direct-acting antiviral (DAA) agents targeting viral proteases and polymerases.
• The HCV non-structural 4B (NS4B) protein, essential for viral replication, remains less characterized but is a promising drug target.

Purpose of the Study:

• To review the current understanding of Hepatitis C virus non-structural 4B (NS4B) protein structure and function.
• To explore novel drug discoveries targeting NS4B for anti-hepatitis C virus therapy.
• To summarize recent advancements in NS4B inhibitor development within the last three years.

Main Methods:

• Literature review of scientific publications and pharmacological studies.
• Analysis of research on Hepatitis C virus non-structural 4B (NS4B) protein functions.
• Compilation of data on novel chemical entities targeting NS4B.

Main Results:

• HCV NS4B protein plays a key role in forming the viral replication complex.
• Various chemical derivatives, including sulfonamides, piperidines, carboxamides, piperazinones, and quinolines, show potential as NS4B inhibitors.
• These novel compounds aim to enhance antiviral efficacy and prevent drug resistance.

Conclusions:

• HCV NS4B is a viable and important target for developing new antiviral therapies.
• Emerging NS4B inhibitors represent a promising avenue for future Hepatitis C virus treatment strategies.
• Continued research into NS4B inhibitors is crucial for combating HCV infection effectively.